This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

6 Stocks Hitting New 52-Week Highs

Arrowhead Research

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Arrowhead Research (ARWR - Get Report) is a development-stage company. Arrowhead is a nanomedicine company engaged in development therapeutic products at the interface of biology and nano-engineering to cure disease and improve human health. This stock is trading up 47% to $79 cents in recent trading after hitting a 52-week high of $1.19 earlier in the day.

Today's Range: $0.71-$1.19

52-week Range: $0.31-$1.19

Volume: 4,850,000

Three-Month Average Volume: 121,682

Arrowhead Research has a market cap of $58.90 million and an enterprise value of $33.86 million. The stock trades at a price-to-book of 3.61 and a price-to-sales of 41.94. The current short interest as a percentage of the float for Arrowhead is a very low 1.3%.

This stock is soaring today after the company announced the publication of data from its subsidiary Ablaris Therapeutics's lead drug candidate, Adipotide, demonstrating weight loss and reduction of body mass index in obese monkeys.

From a technical standpoint, this stock has given back a lot of its gains from earlier in the day when it touched $1.19 a share, and the volume is huge. (It also shows up on today's list of Stocks Rising on Unusual Volume.)

For now, I would avoid this name until it can consolidate some more and find support levels where buyers step in. This move is simply a super spike that's not sustainable in the short term. That said, if the stock can hold above 78 cents, it would be constructive since that's previous resistance level.
3 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
ARWR $5.60 -1.30%
COG $23.82 -1.50%
GNRC $34.77 0.32%
IDSY $5.26 1.90%
RATE $9.20 6.10%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs